Inside Walmart's plan to source more products from American small businesses
Why it matters: Walmart recently confirmed plans to raise some prices as it grapples with the impact of increased tariffs, drawing the ire of President Trump.
The big picture: Walmart U.S. CEO John Furner tells Axios in an exclusive interview that the company wants to give more small American businesses a chance to sell goods at the company, which already devotes about two-thirds of its product spend to goods that are made, grown or assembled in the U.S.
"It's always helpful when you have the shortest supply chain possible," Furner says.
Zoom in: Walmart now has more than half a billion items for sale online, Furner said.
And the company expects to offer three-hour delivery to 95% of the country by the end of 2025, up from 90% today, he added.
The intrigue: Despite the impact of tariffs, Furner said Walmart is not experiencing significant cost increases.
"We're at a point today where inflation is relatively low," he said.
"What we're trying to do is keep prices as low as we can, as long as we can, to not have our customers in a position where they feel like their food bills or basic essentials are starting to rise again," he added.
Inside the room: At a Walmart reception Wednesday in Washington, D.C., several small to mid-size business owners told Axios they are growing their operations after reaching deals to sell products with the retailer.
David Sarnoff, president of Handi-foil, tells Axios his company is adding jobs at its facilities in Illinois to accommodate for growth from sales of its cooking pans at Walmart.
Brian Waddick, founder of sunflower seeds brand Smackin', tells Axios his startup expects to "double or triple" in size in the next 18 months as it launches sales in hundreds of Walmart locations: "We want to be the Gen Z PepsiCo," he says.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. The company rose to prominence during the COVID-19 pandemic thanks to its antiviral drug remdesivir, one of the earliest approved treatments for the virus. However, despite its scientific breakthroughs and commercial achievements, Gilead has lagged behind the broader market over the past ten years, as investors remain cautious about its growth prospects and ability to deliver on its pipeline. That said, Gilead Sciences, Inc. (NASDAQ:GILD)'s cash position remained stable, which makes it one of the best dividend stocks in the pharma sector. In the first quarter of 2025, the company generated $1.8 billion in operating cash flow and had $7.9 billion available in cash and cash equivalents. During the quarter, it also returned $1 billion to investors through dividends. Gilead Sciences, Inc. (NASDAQ:GILD) currently offers a quarterly dividend of $0.79 per share and has a dividend yield of 2.90%, as of July 17. The company has raised its payouts every year since 2015. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Could Buying Lockheed Martin Stock Today Set You Up for Life?
Key Points The medium-term outlook for defense spending is positive, with both the U.S. and other NATO countries looking to ramp up investment. Lockheed Martin is well positioned to benefit from President Trump's defense budget. The company's execution issues have troubled it in recent years, and many defense companies have faced margin pressures. 10 stocks we like better than Lockheed Martin › There's a lot to like about defense giant Lockheed Martin's (NYSE: LMT) stock, but is it enough to make it an investment that investors can feel comfortable with, knowing it will generate life-changing long-term returns? The bulls' case for Lockheed Martin The investment case for the stock is relatively easy to understand. It's based on the enduring need for defense equipment and services, as well as its increasing importance in an age of geopolitical conflict. Not only is President Donald Trump seeking to ramp up the defense budget to a record $1.01 trillion, but NATO has also been enlarged, and its members have recently agreed to invest 5% of their gross domestic product (GDP) on core defense requirements as well as defense and security-related spending by 2035. Moreover, much of the spending, at least in the U.S., focuses on missile defense and tactical missiles, which Lockheed Martin specializes in. Indeed, discussing the matter on an earnings call in April, CEO Jim Taiclet said, "Our 21st century security strategy, where we integrate existing and new satellites, aircraft, ships, missile launchers, and command and control systems with constantly upgradable digital technologies, was tailor-made for [missile defense system] Golden Dome." Furthermore, Lockheed Martin's current backlog of $173 billion represents 2.3 years' worth of sales based on the midpoint of management's guidance for full-year 2025 revenue. It's also worth noting that its core customer, the U.S. government, is a highly reliable payer. Turning to valuation, the midpoint of management's guidance range calls for $23.15 in earnings per share and $6.7 billion in free cash flow (FCF). Based on the current price, it would put the stock at 17.2 times earnings and 16.3 times FCF. They are attractive valuations for a company with such solid growth prospects. So is it that case closed? As usual, investing is rarely that simple. The bears' case for Lockheed Martin The negative case for the stock can be seen in three interrelated arguments: Lockheed Martin's execution challenges in recent years, notably with its most important single program, the F-35 Lightning II Joint Strike Fighter, have damaged confidence in its ability to produce "long-run franchise" programs. Lockheed Martin, like many other defense contractors, including Boeing and RTX, has struggled to achieve margin expansion in recent years, as the U.S. government has become more adept at negotiating contracts, particularly through the use of fixed-price contracts. The current environment is highly conducive to defense spending, but that doesn't guarantee that it will be the case in the future. Lockheed Martin's execution and margin challenges The company's execution challenges are encapsulated in two events this year. First, a Department of Defense description of the proposed 2026 defense budget included reducing F-35 procurement. There's little doubt why procurement has been reduced. The DOD is focusing on making existing F-35s mission-capable (able to perform a core mission) rather than procuring new planes. According to just 51.5% of F-35s were mission-capable in 2024. High-profile delays and issues on the Technology Refresh 3 (TR3) on the F-35 have reduced that percentage. In addition, the cost overrun on the F-35 has been so significant that the military is now considering flying it less to reduce costs. These issues damage confidence in Lockheed Martin, not least as it faces upfront costs on programs in expectation of turning them into "long-run franchises." As such, there are questions about its ability to grow margins in the future. The second issue is the loss of the next-generation air dominance (NGAD) contract to Boeing, a decision highly likely to have been influenced by the issues with the F-35. Long-term defense spending This isn't the place to enter a detailed debate over the sustainability of government spending. Still, it's worth noting that if you are buying defense stocks based on the security of long-term growth in spending from the U.S. government (which currently accounts for two-thirds of NATO spending), then you will be comfortable with the following chart of U.S. public debt to GDP and the idea that the possibility of rising debt levels won't constrain spending on defense and other matters in the future. In addition, it's extremely difficult to predict where global defense priorities will be over the next few years, let alone a lifetime. Is Lockheed Martin stock a buy? On balance, defense stocks appear slightly undervalued; however, Lockheed Martin's issues with the F-35 may not make it the best way to capitalize on a positive medium-term outlook for defense spending. As such, Lockheed Martin isn't likely to be a stock that investors can make a life-changing investment in. Should you buy stock in Lockheed Martin right now? Before you buy stock in Lockheed Martin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lockheed Martin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Lockheed Martin and RTX. The Motley Fool has a disclosure policy. Could Buying Lockheed Martin Stock Today Set You Up for Life? was originally published by The Motley Fool
Yahoo
24 minutes ago
- Yahoo
CVS Health's (CVS) Dividend Outlook: Can the Retail-Pharma Giant Deliver in 2025?
CVS Health Corporation (NYSE:CVS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. CVS Health Corporation (NYSE:CVS)'s retail pharmacy business may be widely recognized, but it represents just a small portion of its broader business. The company also runs a top-tier pharmacy benefits management division and owns Aetna, a major player in the health insurance space. Although CVS Health Corporation (NYSE:CVS)'s stock took a significant hit last year, it has rebounded this year. The stock has surged by over 43% since the start of 2025. The company also reported strong earnings in the first quarter of 2025, with revenues coming in at $94.6 billion. The revenue showed a 7% growth from the same period last year and also beat analysts' estimates by $1.22 billion. CVS Health Corporation (NYSE:CVS) also posted a solid cash position with an operating cash flow of $4.6 billion. The company increased its operating cash flow forecast from around $6.5 billion to roughly $7.0 billion. This cash position has enabled the company to pay uninterrupted dividends to shareholders since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 4.20%, as of July 17. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
